Literature DB >> 18759864

Pioglitazone inhibits homocysteine-induced migration of vascular smooth muscle cells through a peroxisome proliferator-activated receptor gamma-independent mechanism.

Li Li1, Ping-Jin Gao, Rui Xi, Chun-Fang Wu, Ding-Liang Zhu, Jing Yan, Guo-Ping Lu.   

Abstract

1. Peroxisome proliferator-activated receptor (PPAR)-gamma agonists have been demonstrated to exert protective effects against homocysteine (Hcy)-induced pathogenesis. However, the effects of PPAR-gamma agonists on Hcy-induced migration are unknown. In the present study, we examined the effect of pioglitazone on the migration of vascular smooth muscle cells (VSMC) induced by Hcy and the possible mechanism involved. 2. Vascular smooth muscle cells were isolated from the thoracic aortas of male Sprague-Dawley rats. The migration of VSMC was examined using a transwell technique. The generation of intracellular reactive oxygen species (ROS) was measured using the ROS-sensitive fluoroprobe 2',7'-dichlorodihydrofluorescein diacetate. The activity of NAD(P)H oxidase was assessed by lucigenin enhanced chemiluminescence. Activation of p38 mitogen-activated protein kinase (MAPK) was determined by western blotting. 3. The results showed that pioglitazone dose-dependently inhibited the migration of VSMC induced by Hcy. This was not reversed by the PPAR-gamma antagonist GW9662. In addition, pretreatment with the NAD(P)H oxidase inhibitor diphenylene iodonium (DPI), the free radical scavenger N-acetylcysteine and the p38 MAPK inhibitor SB202190 blocked Hcy-induced VSMC migration. Furthermore, we observed that pioglitazone suppressed Hcy-induced intracellular ROS production; similar effects were observed with DPI and NAC. Pioglitazone attenuated Hcy-induced activation of NAD(P)H oxidase. Moreover, pioglitazone blocked Hcy-induced p38 MAPK phosphorylation; similar effects were observed for DPI, NAC and SB202190. 4. The data demonstrate that pioglitazone inhibits Hcy-induced VSMC migration that is independent of PPAR-gamma. Furthermore, part of the biological effect of pioglitazone involves a decrease in the levels of NAD(P)H oxidase derived-ROS and p38 MAPK activation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18759864     DOI: 10.1111/j.1440-1681.2008.05025.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  5 in total

Review 1.  Redox control of vascular smooth muscle migration.

Authors:  Alejandra San Martín; Kathy K Griendling
Journal:  Antioxid Redox Signal       Date:  2010-03-01       Impact factor: 8.401

2.  Emodin Inhibits Homocysteine-Induced C-Reactive Protein Generation in Vascular Smooth Muscle Cells by Regulating PPARγ Expression and ROS-ERK1/2/p38 Signal Pathway.

Authors:  Xiaoming Pang; Juntian Liu; Yuxia Li; Jingjing Zhao; Xiaolu Zhang
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

3.  Pioglitazone Ameliorates Smooth Muscle Cell Proliferation in Cuff-Induced Neointimal Formation by Both Adiponectin-Dependent and -Independent Pathways.

Authors:  Tetsuya Kubota; Naoto Kubota; Hiroyuki Sato; Mariko Inoue; Hiroki Kumagai; Tomokatsu Iwamura; Iseki Takamoto; Tsuneo Kobayashi; Masao Moroi; Yasuo Terauchi; Kazuyuki Tobe; Kohjiro Ueki; Takashi Kadowaki
Journal:  Sci Rep       Date:  2016-10-05       Impact factor: 4.379

Review 4.  Can Pioglitazone Safeguard Patients of Lichen Planus Against Homocysteine Induced Accelerated Cardiovascular Aging and Reduced Myocardial Performance: A Systematic Review.

Authors:  Prachi Balani; Angel R Lopez; Chelsea Mae N Nobleza; Mariah Siddiqui; Parth V Shah; Safeera Khan
Journal:  Cureus       Date:  2020-12-30

5.  Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARgamma stimulation.

Authors:  Federico Biscetti; Giuseppe Straface; Vincenzo Arena; Egidio Stigliano; Giovanni Pecorini; Paola Rizzo; Giulia De Angelis; Luigi Iuliano; Giovanni Ghirlanda; Andrea Flex
Journal:  Cardiovasc Diabetol       Date:  2009-09-08       Impact factor: 9.951

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.